Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes. In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

• Trodusquemine (MSI-1436)
• MEDI-528 (Anti-IL-9)

• MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of obesity and has applicability in type 2 diabetes. Genaera initiated its first-in-man clinical studies in 2Q07.
• MEDI-528 the second core asset out-licensed to MedImmune/Astra Zeneca is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.